Profil
Bernard A.
Fox is the founder of UbiVac, Inc., a company founded in 2005, where he holds the title of Chief Executive Officer & Director.
Currently, Dr. Fox is the Director at Oregon Bioscience Association, Vice President at International Society for Biological Therapy of Cancer, and Laboratory Chief at Earle Chiles Research Institute since 1994.
In his former positions, Dr. Fox served as a Director at NeoPharm, Inc. from 2004 to 2011, Director at InSys Therapeutics, Inc. in 2011, and Director at INSYS Therapeutics, Inc. in 2010.
Postes actifs de Bernard A. Fox
| Sociétés | Poste | Début |
|---|---|---|
| Earle Chiles Research Institute | Corporate Officer/Principal | 01/01/1994 |
International Society for Biological Therapy of Cancer
 International Society for Biological Therapy of Cancer Miscellaneous Commercial ServicesCommercial Services The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI. | Corporate Officer/Principal | - |
UbiVac, Inc.
 UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Fondateur | 01/01/2005 |
Oregon Bioscience Association
 Oregon Bioscience Association Miscellaneous Commercial ServicesCommercial Services The Oregon Bioscience Association is a non-profit membership association that advocates for and promotes the growth and quality of the bioscience industry in the region. The association is based in Portland, OR. The non-profit company seeks to create opportunities for their members through advocacy, cultivation, education, and group purchasing discounts. The association is affiliated with several other organizations, including the Biotechnology Innovation Organization and the Medical Device Manufacturers Association. The bioscience industry in the region has experienced significant growth, with a bio footprint of $10.70 billion and 47,238 jobs created. | Directeur/Membre du Conseil | - |
Anciens postes connus de Bernard A. Fox
| Sociétés | Poste | Fin |
|---|---|---|
NeoPharm, Inc.
 NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Directeur/Membre du Conseil | 02/05/2011 |
InSys Therapeutics, Inc. /Old/
 InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Directeur/Membre du Conseil | 01/05/2011 |
| INSYS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 08/11/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
NeoPharm, Inc.
NeoPharm, Inc. BiotechnologyHealth Technology NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL. | Health Technology |
InSys Therapeutics, Inc. /Old/
InSys Therapeutics, Inc. /Old/ Pharmaceuticals: GenericHealth Technology InSys Therapeutics, Inc. is a pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care. The company's product pipeline targeting cancer-supportive care and cancer therapy that it believe can be developed cost efficiently and, if approved, commercialized through a targeted commercial organization. Its supportive care product candidates include Fentanyl SL Spray, a proprietary, fast-acting sublingual fentanyl spray for the treatment of breakthrough cancer pain, and its family of dronabinol product candidates for the treatment of chemotherapy-induced nausea and vomiting and appetite stimulation in AIDS patients. The company was founded by Dr. S. George Kottayil and John N. Kapoor on October 18, 2002 and is headquartered in Phoenix, AZ. | Health Technology |
International Society for Biological Therapy of Cancer
International Society for Biological Therapy of Cancer Miscellaneous Commercial ServicesCommercial Services The International Society for Biological Therapy of Cancer operates as a professional society of influential scientists, academicians, researchers, clinicians, and government representatives. The non-profit company is based in Milwaukee, WI. | Commercial Services |
| Earle Chiles Research Institute | |
UbiVac, Inc.
UbiVac, Inc. Pharmaceuticals: MajorHealth Technology UbiVac LLC engages in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases. The company was founded by Bernard A. Fox and Hong-Ming Hu in 2005 and is headquartered in Portland, OR. | Health Technology |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
Oregon Bioscience Association
Oregon Bioscience Association Miscellaneous Commercial ServicesCommercial Services The Oregon Bioscience Association is a non-profit membership association that advocates for and promotes the growth and quality of the bioscience industry in the region. The association is based in Portland, OR. The non-profit company seeks to create opportunities for their members through advocacy, cultivation, education, and group purchasing discounts. The association is affiliated with several other organizations, including the Biotechnology Innovation Organization and the Medical Device Manufacturers Association. The bioscience industry in the region has experienced significant growth, with a bio footprint of $10.70 billion and 47,238 jobs created. | Commercial Services |
